Overall survival (OS) · women with metastatic triple‐negative breast cancer (mTNBC)
Platinum showed no clear difference in overall survival (OS) compared with non‐platinum regimens (moderate certainty).
1 finding from 1 review
Time to progression · women with metastatic triple‐negative breast cancer (mTNBC)
It is very uncertain whether platinum changes progression‐free survival/time to progression (PFS/TTP) compared with non‐platinum regimens (very low certainty).
1 finding from 1 review
Tumour response · women with metastatic triple‐negative breast cancer (mTNBC)
Platinum may leads to higher objective tumour response rate (OTRR) (assessable participants) compared with non‐platinum regimens (low certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review
Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).
1 finding from 1 review
Hearing loss · children with cancer treated with platinum‐based therapy
Continuous platinum infusion showed no clear difference in hearing loss (asymptomatic and symptomatic disease according to… compared with bolus platinum infusion (low certainty).
1 finding from 1 review
Tinnitus ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · children with cancer treated with platinum‐based therapy
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Adverse effects: toxic death (no definition provided) · children with cancer treated with platinum‐based therapy
Continuous platinum infusion showed no clear difference in adverse effects: toxic death (no definition provided) compared with bolus platinum infusion (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower overall survival compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
12‐month survival rates · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower 12‐month survival rates compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower progression‐free survival compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Tumor response rate · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to higher tumor response rate compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Toxicity – anemia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet showed no clear difference in toxicity – anemia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Toxicity – neutropenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – neutropenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Toxicity – thrombocytopenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – thrombocytopenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review